Previous 10 | Next 10 |
SAN DIEGO, June 27, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT), a leading RNA medicines company focused on the development and commercialization of therapeutics towards rare, liver and respiratory diseases with significant unmet medical need, today announced...
Gainers: Melinta Therapeutics (NASDAQ: MLNT ) +180% . Arcturus Therapeutics (NASDAQ: ARCT ) +37% . Hebron Technology (NASDAQ: HEBT ) +26% . MYOS RENS Technology (NASDAQ: MYOS ) +22% . Armata Pharmaceuticals (NYSEMKT: ARMP ) +19% . AquaBounty Technologies (NASDAQ: AQB ) +19% . D...
Ultragenyx Pharmaceutical ( RARE ) and Arcturus Therapeutics ( ARCT +37.7% ) say they will expand their licensing deal and research collaboration to discover and develop mRNA, DNA and siRNA therapeutics for up to 12 rare disease targets. More news on: Ultragenyx Pharmaceutical Inc., Ar...
Scope of the collaboration expands to include up to 12 rare disease targets and includes Arcturus nucleic acid technologies to enable mRNA, DNA, and siRNA therapeutics $30 million of upfront payments to Arcturus, including $6 million cash for collaboration agreement amendment an...
SAN DIEGO, June 13, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) (the “Company”), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that it has...
SAN DIEGO, May 20, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT) (the “Company”), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that Pad Chivukula, P...
Arcturus Therapeutics (NASDAQ: ARCT ): Q1 GAAP EPS of -$0.68 misses by $0.10 . More news on: Arcturus Therapeutics Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...
SAN DIEGO, May 13, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today reported its financial results for the quarter ended March 31...
Most developers of therapies to treat nonalcoholic steatohepatitis (NASH) are under modest pressure as investors remain unimpressed with the initial announcements from The International Liver Congress in Vienna. More news on: Intercept Pharmaceuticals, Inc., Gilead Sciences, Inc., Enanta P...
CORAL GABLES, FL / ACCESSWIRE / March 28, 2019 / The healthcare stock market has been a hotbed of excitement in the first few months of 2019 as companies in the industry have focused their efforts on developing innovative technologies and treatments for consumers. The fact of the matter is...
News, Short Squeeze, Breakout and More Instantly...
Arcturus Therapeutics Ltd. Company Name:
ARCT Stock Symbol:
NASDAQ Market:
Arcturus Therapeutics Ltd. Website:
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, toda...
2024-07-02 10:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for ARCT on July 2, 2024 08:19AM ET. The previous analyst recommendation was Overweight. ARCT was trading at $23.66 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
ARCT-810 Phase 2 study completed enrollment at 0.3 mg/kg dose level in Europe with data expected later this year ARCT-810 to expand Phase 2 clinical program in the U.S. to enroll patients with more severe disease ARCT-032 IND for Phase 2 multiple ascending dose study to be submitt...